RPG Life Sciences Ltd
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]
- Market Cap ₹ 4,394 Cr.
- Current Price ₹ 2,657
- High / Low ₹ 2,715 / 1,731
- Stock P/E 40.1
- Book Value ₹ 366
- Dividend Yield 0.90 %
- ROCE 25.7 %
- ROE 19.3 %
- Face Value ₹ 8.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 7.26 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE 1000
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 653 | 708 | |
| 493 | 560 | |
| Operating Profit | 161 | 148 |
| OPM % | 25% | 21% |
| 95 | 29 | |
| Interest | 2 | 2 |
| Depreciation | 21 | 21 |
| Profit before tax | 233 | 154 |
| Tax % | 21% | 25% |
| 183 | 115 | |
| EPS in Rs | 110.79 | 69.64 |
| Dividend Payout % | 22% | 34% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 42% |
| 3 Years: | 41% |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 13 | 13 |
| Reserves | 517 | 592 |
| -0 | 20 | |
| 127 | 168 | |
| Total Liabilities | 658 | 793 |
| 172 | 197 | |
| CWIP | 16 | 23 |
| Investments | 127 | 85 |
| 343 | 488 | |
| Total Assets | 658 | 793 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 78 | 56 | |
| -42 | 86 | |
| -27 | -21 | |
| Net Cash Flow | 9 | 122 |
| Free Cash Flow | 151 | -9 |
| CFO/OP | 81% | 63% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 48 | 60 |
| Inventory Days | 159 | 179 |
| Days Payable | 135 | 141 |
| Cash Conversion Cycle | 72 | 99 |
| Working Capital Days | 45 | 64 |
| ROCE % | 26% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| API Revenue Share % of total revenue |
|
||||||||||
| Domestic Formulations Revenue Share % of total revenue |
|||||||||||
| International Formulations Revenue Share % of total revenue |
|||||||||||
| Sales Force Productivity (PCPM - Overall) INR Lakhs per rep per month |
|||||||||||
| New Product Contribution (DF sales from launches since FY19) % of DF sales |
|||||||||||
| DF Growth vs IPM Market Growth % YoY growth |
|||||||||||
| Doctors Enrolled on RPG Serv Platform Number of doctors |
|||||||||||
| Specialty Sales Force Productivity (PCPM) INR Lakhs per rep per month |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Jul - The copy of Notice of 19th AGM published in today''s newspaper in Business Standard (English) and Mumbai ....
-
Intimation Under Regulation 30 Regarding Letter Dispatched To The Shareholders Of The Company
2 Jul - RPG Life Sciences scheduled 19th AGM on July 23, 2026 and shared FY2025-26 annual report link.
- Notice Of 19Th Annual General Meeting Of The Company 1 Jul
-
Business Responsibility and Sustainability Reporting (BRSR)
1 Jul - Annual Report FY26, BRSR and AGM notice for July 23, 2026.
- Reg. 34 (1) Annual Report. 1 Jul
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Concalls
-
May 2026TranscriptPPT REC
-
Apr 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Oct 2025Transcript PPT REC
-
Jul 2025TranscriptAI SummaryPPT
-
Jun 2025TranscriptAI SummaryPPT
-
Apr 2025Transcript PPT REC
-
Nov 2024TranscriptAI SummaryPPT
-
Sep 2024TranscriptPPTREC
-
Jul 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptAI SummaryPPT
-
Oct 2023Transcript PPT
-
Jul 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Oct 2022Transcript PPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Jan 2022TranscriptAI SummaryPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Jun 2019TranscriptAI SummaryPPT
-
Jun 2018TranscriptAI SummaryPPT
-
Nov 2017TranscriptAI SummaryPPT
-
Jun 2017TranscriptAI SummaryPPT
-
Nov 2016TranscriptAI SummaryPPT
-
Jun 2016TranscriptAI SummaryPPT
Business Overview:[1]
RPGLS is a part of the RPG Group. It started as a joint venture with G.D Searle and was renamed when G.D Searle withdrew its India operations. Currently, the group has major listed companies like KEC International, CEAT, Zensar Tech, etc.
RPGLS is an integrated research based pharmaceutical company operating in domestic and international markets in branded formulations, global generics and APIs